Bioventus Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Class A Common Stock · Class B Common Stock · Additional Paid-in Capital · Accumulated other comprehensive income (loss) · Accumulated Deficit · Non-controlling Interest · Total Stockholders’Equity | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||||||||||||
| December 31, 2022 | 62,063,014 | $62 | 15,786,737 | $16 | $490,576 | $(110) | $(165,306) | $86,984 | $412,222 | ||||||||
| Issuance of Class A common stock for equity plans | 1,204,422 | 1 | — | — | 777 | — | — | — | 778 | ||||||||
| Net loss | — | — | — | — | — | — | (156,230) | (39,395) | (195,625) | ||||||||
| Equity-based compensation | — | — | — | — | 2,388 | — | — | 334 | 2,722 | ||||||||
| Change in noncontrolling interest allocation | — | — | — | — | 513 | — | — | (513) | — | ||||||||
| Distributions to members | — | — | — | — | — | — | — | (111) | (111) | ||||||||
| Other comprehensive income | — | — | — | — | — | 904 | — | 228 | 1,132 | ||||||||
| December 31, 2023 | 63,267,436 | $63 | 15,786,737 | $16 | $494,254 | $794 | $(321,536) | $47,527 | $221,118 | ||||||||
| Issuance of Class A common stock for equity plans | 2,490,905 | 3 | — | — | 2,439 | — | — | — | 2,442 | ||||||||
| Net loss | — | — | — | — | — | — | (36,125) | (10,924) | (47,049) | ||||||||
| Change in noncontrolling interest allocation | — | — | — | — | 495 | — | — | (495) | — | ||||||||
| Equity-based compensation | — | — | — | — | 10,904 | — | — | 2,370 | 13,274 | ||||||||
| Other comprehensive loss | — | — | — | — | — | (3,367) | — | (814) | (4,181) | ||||||||
| December 31, 2024 | 65,758,341 | $66 | 15,786,737 | $16 | $508,092 | $(2,573) | $(357,661) | $37,664 | $185,604 | ||||||||
| Issuance of Class A common stock for equity plans | 1,339,375 | 1 | — | — | 2,073 | — | — | — | 2,074 | ||||||||
| Tax withholdings on equity-based compensation awards | — | — | — | — | (9) | — | — | — | (9) | ||||||||
| Net income | — | — | — | — | — | — | 22,732 | 4,542 | 27,274 | ||||||||
| Change in noncontrolling interest allocations | — | — | — | — | 72 | — | — | (72) | — | ||||||||
| Equity-based compensation | — | — | — | — | 10,623 | — | — | 2,050 | 12,673 | ||||||||
| Distributions to members | — | — | — | — | — | — | — | (5) | (5) | ||||||||
| Cash flow hedging, net | — | — | — | — | — | (802) | — | (189) | (991) | ||||||||
| Other comprehensive income | — | — | — | — | — | 1,475 | — | 352 | 1,827 | ||||||||
| December 31, 2025 | 67,097,716 | $67 | 15,786,737 | $16 | $520,851 | $(1,900) | $(334,929) | $44,342 | $228,447 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.